PepGen shares are trading lower. The company announced clinical data from the first dose cohort of PGN-EDO51.
Portfolio Pulse from Benzinga Newsdesk
PepGen shares are trading lower after the company announced clinical data from the first dose cohort of PGN-EDO51.
July 30, 2024 | 8:59 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
PepGen shares are experiencing a decline following the release of clinical data from the first dose cohort of PGN-EDO51.
The release of clinical data can significantly impact biotech companies' stock prices. In this case, the market has reacted negatively to the data from the first dose cohort of PGN-EDO51, leading to a decline in PepGen's share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100